Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation

European Heart Journal, Supplement

Volumn 7, Issue C, 2005, Pages

  Schulman, Sam ^a,b   Beyth, Rebecca J ^c,d  

^a HHS General Hospital   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Prediction; Reversal

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANDROGEN; ANTICOAGULANT AGENT; ANTIVITAMIN K; CIMETIDINE; CITALOPRAM; CLOFIBRATE; COTRIMOXAZOLE; DESMOPRESSIN; DISULFIRAM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GINKGO BILOBA EXTRACT; GLUCAGON; IDRAPARINUX; MELAGATRAN; METRONIDAZOLE; OXYPHENBUTAZONE; PARACETAMOL; PAROXETINE; PHENYLBUTAZONE; PHYTOMENADIONE; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SALICYLIC ACID DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFINPYRAZONE; TAMOXIFEN; THROMBIN INHIBITOR; THYROID HORMONE; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DISEASE PREDISPOSITION; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GENETIC SUSCEPTIBILITY; GINKGO BILOBA; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HEMATOMA; HEMOPERICARDIUM; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UROGENITAL TRACT DISEASE;

EID: 18744413926     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui018     Document Type: Review

References (70)

1. Frykman V, Beermann B, Rydén L et al. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-1959.
2. Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-46.
3. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA 1999;281:1830-1835.
4. Segal JB, McNamara RL, Miller MR et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 2000;15:56-67.
5. Go AS, Hylek EM, Phillips KA et al. Effectiveness and safety of warfarin to prevent thromboembolism among 13559 patients with atrial fibrillation: how well do results of randomized trials apply to clinical practice? The ATRIA Study. Circulation 2002;106:515.
6. van Walraven C, Hart RG, Singer DE. Oral anticoagulants versus aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-2448.
7. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1:175-179.
8. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000;31:817-821.
9. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-539.
10. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
11. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Fngl J Med 1992;327:1406-1412.
12. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.
13. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355.
14. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):429S-456S.
15. Torn M, van der Meer FJM, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy. Arch Intern Med 2004;164:668-673.
16. Gulløv AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Arch Intern Med 1999;159:1322-1328.
17. Blackshear JL, Halperin JL, Hart RG et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
18. Altman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427-431.
19. Saour JN, Sieck JO, Mamo LA et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. (Comment). N Engl J Med 1990;322:428-432.
20. Turpie AG, Gent M, Laupacis A et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-529.
21. Hull R, Hirsh J, Jay R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
22. Ageno W, Turpie AG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. Thromb Res 1998;91:237-240.
23. Doecke CJ, Cosh DG, Gallus AS. Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response. Aust N Z J Med 1991;21:319-324.
24. Poller L, Shiach CR, MacCallum PK et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998;352:1505-1509.
25. Körtke H, Körfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 2001;72:44-48.
26. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428.
27. Fihn SD, McDonell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993;118: 511-520.
28. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-152.
29. Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979;42:128-132.
30. Schulman S. Oral anticoagulation. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds Williams Hematology. 6th ed. New York: McGraw-Hill; 2001. p1777-1792.
31. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996;156:409-416.
32. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-2175.
33. Oldenburg J, Kriz K, Wuillemin WA et al. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 2001;85: 454-457.
34. Aithal GP, Day CP, Kesteven PJL et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1998;353:717-719.
35. Shikata E, Ieiri I, Ishiguro S et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004;103:2630-2635.
36. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
37. Palareti G, Legnani C, Lee A et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810.
38. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
39. Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3): 237S-310S.
40. White RH, McKittrick T, Takakuwa J et al. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med 1996;156:1197-1201.
41. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in out-patients taking warfarin. Ann Intern Med 1994;120:897-902.
42. van der Meer FJM, Rosendaal FR, Vandenbroucke JP et al. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76:12-16.
43. Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1997; 124:970-979.
44. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99.
45. Kuijer PMM, Hutten BA, Prins MH et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457-460.
46. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation. Physicians' fears often unfounded. Arch Intern Med 2003;163:1580-1586.
47. Hart RG, Halperin JL, Pearce LA et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138:831-838.
48. Crowther MA, Julian J, McCarty D. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-1553.
49. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of overwarfarinization. Br J Haematol 2000;109:537-539.
50. Gunther KE, Conway G, Leibach L et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10. Thromb Res 2004;113:205-209.
51. Makris M, Greaves M, Phillips WS et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480.
52. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003;349:675-683.
53. Schulman S, Johnsson H. Heparin, DDAVP and the bleeding time. Thromb Haemost 1991;65:242-244.
54. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
55. Teng R, Sarich TC, Eriksson UG et al. A pharmacokinetic study of the combined administration of amiodarone and ximetagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 2004;44:1063-1071.
56. Bredberg E, Andersson TB, Frison L et al. Ximetagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42: 765-777.
57. Sarich TC, Schützer K-M, Dorani H et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004;44:928-934.
58. Sarich TC, Schützer K-M, Wollbratt M et al. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximetagatran in healthy volunteers. J Clin Pharm 2004;44:935-941.
59. Fager G, Cullberg M, Eriksson-Lepkowska M et al. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetyl-salicylic acid. Eur J Clin Pharmacol 2003;59:283-289.
60. Johansson LC, Frison L, Logren U et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-392.
61. Johansson LC, Andersson M, Fager G et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy mate volunteers. Clin Pharmacokinet 2003;42:475-484.
62. Sarich TC, Teng R, Peters GR et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003;42:485-492.
63. Eriksson UG, Bredberg U, Gislén K et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59:35-43.
64. Sarich TC, Johansson S, Schützer K-M et al. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 2004;44:388-393.
65. Carlsson SC, Attman P-O, Samuelsson O et al. Antithrombotic effects and pharmacokinetics of the direct thrombin inhibitor melagatran administered in dialysate in a porcine model of hemodialysis. (Abstract SU-PO474) J Am Soc Nephrol 2004;15:638A.
66. Elg M, Carlsson S, Gustafsson D. Effects of activated prothrombin complex concentrate or recombinant Factor Vila on bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001;101:145-157.
67. Gruber A, Carlsson S, Kotzé H et al. Activated factor VII is hemostatic without promoting thrombus propagation. (Abstract 2998) Blood 2003;102:809a.
68. Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant factor Vila to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106: 2550-2554.
69. Bijsterveld NR, Vink R, van Aken BE et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653-658.
70. Wolzt M, Levi M, Sarich TC et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004;91:1090-1096.